CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the publication of a study in the journal of Proceedings of National Academy of Sciences (PNAS) that applies the company’s ProtoArray® technology to identify new autoantigens associated with ovarian cancer. Ovarian cancer is the fifth leading cause of cancer deaths among women and is very difficult to detect before it spreads to adjacent tissues and organs.
